Consequently, we generated a second variant antibody, E60-A330L, to assess whether the loss of C1q binding or the loss of FcγR binding explained the inability of E60-N297Q to mediate ADE. This evidence concerns the gene FCGR2A and acute disseminated encephalomyelitis.